FDA Fast Track Designation is a significant regulatory milestone that can expedite the development and review process of promising treatments. For Candel Therapeutics, this designation for CAN-3110 not only validates the potential of their therapy but also enhances the company's credibility and could positively influence investor sentiment. The designation is likely to have a favorable impact on the stock price in the short term, given the increased attention and optimism surrounding accelerated development and potential market entry.